PHATHOM PHARMACEUTICALS INC (PHAT) Stock News

NASDAQ:PHAT - US71722W1071 - Common Stock

12.1 USD

-0.24 (-1.94%)

Last: 9/8/2025, 12:18:26 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PHAT Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

14 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

17 days ago - By: Zacks Investment Research

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

19 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

a month ago - By: The Motley Fool

Phathom (PHAT) Q2 Revenue Jumps 441%

a month ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

19 days ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

a month ago - By: Zacks Investment Research - Mentions: BOLT

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

a month ago - By: Zacks Investment Research - Mentions: MNKD

MannKind (MNKD) Reports Break-Even Earnings for Q2

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

a month ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Phathom Pharmaceuticals - Mentions: SAGE

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

3 months ago - By: Benzinga - Mentions: DDI CLDX BG DAR ...

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

3 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)